A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics

Can resveratrol supplementation affect biomarkers of inflammation and oxidative stress? An umbrella meta-analysis

Several meta-analyses exist in supporting the positive effects of resveratrol on inflammatory and oxidative stress biomarkers; however, the finding of some studies is inconsistent. Therefore, the objective of the current study was to investigate the effects of resveratrol on inflammatory and oxidative stress biomarkers in adults. Up until April 2022, we conducted a thorough and systematic search in PubMed, Scopus, Web of Science, Embase, and Google Scholar. Our results from 15 meta-analyses indicated that the resveratrol supplementation meaningfully decrease serum CRP (ES = −0.38, 95 % CI: −0.47, −0.30; p < 0.001) and TNF-α (ES = −0.32; 95 % CI: −0.54, −0.11; p = 0.004). However, the effect of resveratrol on IL-6, TAC, GPx, and SOD activity was not significant. The current umbrella meta-analysis supports the alleviating effects of resveratrol on inflammatory markers but does not suggest any beneficial effect on oxidative stress biomarkers. Therefore, to support this evidence, larger and well-designed trials are required

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

Abstract Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics